1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
Real-time Euronext Paris  -  05/19 08:57:47 am EDT
100.08 EUR   -0.83%
05/18TRANSCRIPT : Sanofi - Special Call
CI
05/17Sanofi Announces New Nirsevimab Data Analyses Reinforce Efficacy Against RSV
CI
05/17ASCO - New data from fast-growing innovative Oncology pipeline and portfolio to be presented at 2022 ASCO Annual Meeting
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SANOFI : JP Morgan reiterates its Buy rating

01/26/2022 | 02:22am EDT

Analyst Richard Vosser from JP Morgan research considers the stock attractive and recommends it with a Buy rating. The target price is unchanged and still at EUR 105.


© MarketScreener with dpa-AFX Analyser 2022
All news about SANOFI
05/18TRANSCRIPT : Sanofi - Special Call
CI
05/17Sanofi Announces New Nirsevimab Data Analyses Reinforce Efficacy Against RSV
CI
05/17ASCO - New data from fast-growing innovative Oncology pipeline and portfolio to be pres..
AQ
05/17MARKETSCREENER'S WORLD PRESS REVIEW : May 17, 2022
05/17Unilever, Uber, Zurich Call For 2035 Ban On Combustion Engines In Europe
MT
05/16Sanofi - Sarclisa (isatuximab) combination provides unprecedented median progression fr..
AQ
05/16Sarclisa® (isatuximab) combination provides unprecedented median progression free surv..
AQ
05/16Sanofi Says Multiple Myeloma Combination Therapy Shows Longer Progression-Free Survival..
MT
05/16Sanofi To Appeal French Court Ruling To Compensate Family For Epilepsy Drug Side Effect..
MT
05/15Sanofi Says Phase 3 Study of Sarclisa Showed Longer Progression-Free Survival
DJ
More news
Analyst Recommendations on SANOFI
More recommendations
Financials
Sales 2022 41 739 M 43 802 M 43 802 M
Net income 2022 7 981 M 8 375 M 8 375 M
Net Debt 2022 6 544 M 6 868 M 6 868 M
P/E ratio 2022 15,8x
Yield 2022 3,50%
Capitalization 126 B 132 B 132 B
EV / Sales 2022 3,18x
EV / Sales 2023 2,94x
Nbr of Employees 95 442
Free-Float 88,3%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 100,92 €
Average target price 114,97 €
Spread / Average Target 13,9%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Director
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI13.93%132 243
JOHNSON & JOHNSON2.59%461 811
PFIZER, INC.-14.65%282 789
ABBVIE INC.12.58%269 361
ELI LILLY AND COMPANY6.87%265 718
ROCHE HOLDING AG-15.26%264 329